Delivery Order HHSN261201200034I-HHSN26100007
Award Date 6/15/15
Potential Completion Date 5/31/21
Potential Value $846K
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Houston, TX 77030, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Cancer Institute issued a delivery order to The University of Texas M.D. Anderson Cancer Center on September 20, 2013, with a ceiling value of $999,843.18 under the Cancer Prevention Agent Development Program 2012-2017 IDIQ for a randomized Phase II trial of low-dose aspirin versus placebo in high-risk individuals with CT screen-detected lung nodules. The Cancer Prevention Agent Development Program is an NCI indefinite delivery contract supporting early-phase clinical research in...
- The National Cancer Institute issued a delivery order to The University of Texas MD Anderson Cancer Center on September 24, 2015, with a ceiling value of $4.2 million under the Cancer Prevention Agent Development Program 2012-2017 IDIQ for core infrastructure support of early-phase clinical research. Place of performance is Houston, TX. The order is priced on a cost-no-fee basis with an ultimate completion date of September 23, 2019. This delivery order represents Option 2 core infrastructure...
- This is a firm fixed price delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson) in the amount of $400,411.43. The contract was issued under the PREVENT Cancer Program (PREVENT) contract vehicle and supports the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS project with a period of performance through...
- This is a delivery order contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center (MD Anderson) valued at $658,199.33. The contract is for a phase I dose escalation study of a topical cancer prevention agent, bexarotene, in women at high risk for breast cancer. It is part of the NCI's Cancer Prevention Agent Development Program, an early-phase clinical research initiative. The contract does not have a set-aside designation. MD Anderson is a...
- This is a firm fixed-price delivery order contract awarded by the Department of Health and Human Services, National Institutes of Health, National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract, valued at $979,494.00, is for research to determine dosing regimens of the drug erlotinib in combination with sulindac for the prevention of colorectal cancer while reducing agent toxicity. The research is part of the...
- This is a firm fixed price delivery order awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract, valued at $728,679.40, is for research to support the "Prevention of Hepatocellular Carcinoma (HCC) Associated with Non-Alcoholic Steatohepatitis (NASH)". The contract is part of the National Cancer Institute's...
- This is a Delivery Order issued against the National Institutes of Health's PREVENT Cancer Program (PREVENT) Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The award, valued at $4,445.48, was made to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a "CONTRACT ORIENTATION AND KICKOFF MEETING" related to the PRECLINICAL PREVENT CANCER PROGRAM initiative. The award has an ultimate completion date of December 31, 2015 and does...
- The National Cancer Institute issued a $1,340,619.47 delivery order to The University of Texas MD Anderson Cancer Center on September 20, 2013, for a Phase IB biomarker trial of naproxen in patients at risk for DNA mismatch repair deficient colorectal cancer under the Cancer Prevention Agent Development Program 2012–2017 IDIQ. The Cancer Prevention Agent Development Program supports early-phase clinical research in cancer prevention. Place of performance is Houston, TX. The order is priced on...
- This is a delivery order awarded by the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) for $591,907.50. The order is part of the NCI Cancer Genome Atlas Program Tissue Purchase indefinite delivery contract, which facilitates the provision of tissue samples and data from various cancer types to support the Cancer Genome Atlas (TCGA) program. This work is funded through the American Recovery and Reinvestment Act (ARRA). The delivery order does...
- This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is part of the PREVENT Cancer Program, a preclinical research initiative focused on developing prevention strategies for breast cancer. The $714,123.60 contract supports "TARGETING THE MTOR PATHWAY FOR THE PREVENTION OF...